U.S. stocks are hitting record highs on an almost-daily basis as we close in on the end of the year.
But the whipsawing we've had to endure to reach this point is enough to give you saddle sores.
The Standard & Poor's 500 Index has gained a healthy 11.6% in 2014 through the closing bell on Friday. From Sept. 18 to Oct. 15, however, the bellwether index fell 7.4%. The downturn ended quickly, and stocks reversed course. In the month that followed, through Nov. 14, the S&P 500 surged 9.5%.
On three other occasions this year, the S&P endured sell-offs of 4% or more.
It's been downright dizzying. But for us, a ruckus of a market like this can be a fantastic opportunity.
Today, I want to show you my secret "risk-busting" strategy that's perfect for rough rides such as this. It's just the tool you can use to turn a volatile market to your advantage.
Keep reading, and I'll show you how to harness this strategy out on the range...
Buy Some Fear
This is what's happening out there in the markets. As the markets keep reaching new record highs, investors get nervous and panic sell.
That can leave long-term investors who believe in their stocks shaking their heads in bewilderment.
But one of my favorite trading tools lets us buy other investors' fear in an easy-to-use, systematic way. It's like "Mr. Market" is dropping $100 bills on the sidewalk - with this strategy, we can pick them up.
I call it the Cowboy Split. Simply put, it means making staggered entries.
Here's how it works. You buy less than your usual amount of shares - say, half - of a tech stock you like at market. Then, you put in a "lowball limit order" to buy the rest at a discount - say, 20% or even 25%.
With a lowball limit order - more commonly known as a "buy limit order" - you tell your broker to buy more of the stock at or below that specified price.
If a $100 stock you believe in keeps rising - good news! - your order is never filled. However, if it falls to $80, you pick up more shares at a discount - and make even greater gains when the stock starts moving again.
For individual investors, this is a great way to invest for the long haul while turning the market's volatility to your advantage.
That's why you all should use this strategy on a regular basis.
Now then, let's take the Cowboy Split for a spin.
About the Author
Michael A. Robinson is a 36-year Silicon Valley veteran and one of the top tech and biotech financial analysts working today. That's because, as a consultant, senior adviser, and board member for Silicon Valley venture capital firms, Michael enjoys privileged access to pioneering CEOs, scientists, and high-profile players. And he brings this entire world of Silicon Valley "insiders" right to you...
- He was one of five people involved in early meetings for the $160 billion "cloud" computing phenomenon.
- He was there as Lee Iacocca and Roger Smith, the CEOs of Chrysler and GM, led the robotics revolution that saved the U.S. automotive industry.
- As cyber-security was becoming a focus of national security, Michael was with Dave DeWalt, the CEO of McAfee, right before Intel acquired his company for $7.8 billion.
This all means the entire world is constantly seeking Michael's insight.
In addition to being a regular guest and panelist on CNBC and Fox Business, he is also a Pulitzer Prize-nominated writer and reporter. His first book Overdrawn: The Bailout of American Savings warned people about the coming financial collapse - years before the word "bailout" became a household word.
Silicon Valley defense publications vie for his analysis. He's worked for Defense Media Network and Signal Magazine, as well as The New York Times, American Enterprise, and The Wall Street Journal.
And even with decades of experience, Michael believes there has never been a moment in time quite like this.
Right now, medical breakthroughs that once took years to develop are moving at a record speed. And that means we are going to see highly lucrative biotech investment opportunities come in fast and furious.
To help you navigate the historic opportunity in biotech, Michael launched the Bio-Tech Profit Alliance.
His other publications include: Strategic Tech Investor, The Nova-X Report, Bio-Technology Profit Alliance and Nexus-9 Network.